Measure FFR | 合法醫療器材資訊網

Youhaveoptionsincoronaryphysiology,FractionalFlowReserve(FFR)calculatesPd/Paduringmaximalhyperemia,Diastolichyperemia-FreeRatio™ ...

*MACCE is a composite of all-cause death, stroke, MI, and any repeat revascularization 1. The SYNTAX II Trial studied the SYNERGY Bioabsorbable Polymer Stent in patients with either CTO or three vessel disease. The SYNTAX I trial studied the TAXUS Express2 drug eluting stent in patients with either Left Main or three vessel disease. Banning, Adrian, MBBS, MD. Clinical outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 5-year results of the SYNTAX II study. ESC Congress 2021. 2. FAME I: Tonino et al. N Engl J Med 2009;360(3):213​ FAME II: De Bruyne, et al. N Engl J Med 2014;371:1208 3. DEFINE PCI Trial: All BSC internal info cites this “Presented by Manesh Patel, MD at TCT Connect 2020.”